Radiation enhancement of head and neck squamous cell carcinoma by the DualPI3K/mTOR Inhibitor PF-05212384

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2792-2801

  Leiker, Andrew J ^a,b   DeGraff, William ^a   Choudhuri, Rajani ^a   Sowers, Anastasia L ^a   Thetford, Angela ^a   Cook, John A ^a   Van Waes, Carter ^c   Mitchell, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEDATOLISIB; H2AX GAMMA; HISTONE H2AX; KI 67 ANTIGEN; PROTEIN KINASE B; PROTEIN P4EBP1; PS6 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; 1-(4-((4-(DIMETHYLAMINO)PIPERIDIN-1-YL)CARBONYL)PHENYL)-3-(4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL)UREA; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; RADIOSENSITIZING AGENT; TARGET OF RAPAMYCIN KINASE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; FIBROBLAST; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA CELL LINE; TISSUE SECTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; DISEASE MODEL; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG SCREENING; GENE SILENCING; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIAZINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941966145     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3279     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-Term survivors of head and neck cancer. Cancer 2014;120: 1507-13.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
4. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
5. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
6. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, et al. Head and neck cancers. J Natl Compr Canc Netw 2011;9:596-650.
7. The cancer genome atlas [http://cancergenome.nih.gov/]. [cited March 22nd, 2015].
8. The cancer genome atlas network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517: 576-82.
9. Broek RV, Mohan S, Eytan DF, Chen Z, Van Waes C. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies. Oral Dis 2013 Nov 12. [Epub ahead of print].
10. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: Attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011;15:63-74.
11. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013;4:e875.
12. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22:5866-75.
13. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003;159:283-300.
14. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-92.
15. Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, et al. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res 2014;20:110-9.
16. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003;56: 846-53.
17. Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-Type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013;19:3808-19.
18. Kim KW, Myers CJ, Jung DK, Lu B. NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant nonsmall cell lung carcinoma. Genes Cancer 2014;5:293-302.
19. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012;72:239-48.
20. Potiron VA, Abderrahmani R, Giang E, Chiavassa S, Di Tomaso E, Maira SM, et al. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. Radiother Oncol 2013;106:138-46.
21. Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-And DNA-PKCs-mediated DNA damage responses. Neoplasia 2012;14:34-43.
22. Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 2014;20:1235-48.
23. Davis AJ, So S, ChenDJ. Dynamics of the PI3K-like protein kinase members ATM and DNA-PKcs at DNA double strand breaks. Cell Cycle 2010; 9:2529-36.
24. Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov 2013;12: 526-42.
25. Moding EJ, Lee CL, Castle KD, Oh P, Mao L, Zha S, et al. Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. J Clin Invest 2014;124:3325-38.
26. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50.
27. Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, et al. Bis(morpholino-1, 3, 5-Triazine) derivatives: potent adenosine 50-Triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem 2010;53:2636-45.
28. ReissM, Brash DE, Munoz-Antonia T, Simon JA, Ziegler A, Vellucci VF, et al. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 1992;4:349-57.
29. Albright N. Computer programs for the analysis of cellular survival data. Radiat Res 1987;112:331-40.
30. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16:2076-84.
31. Soule BP, Simone NL, DeGraff WG, Choudhuri R, Cook JA, Mitchell JB. Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines. Radiat Oncol 2010;5:8, 717X-5-8.
32. Yoshizumi T, Brady SL, Robbins ME, Bourland JD. Specific issues in small animal dosimetry and irradiator calibration. Int J Radiat Biol 2011;87: 1001-10.
33. Alvarez ML, Done SC. SYBR(R) green and TaqMan(R) quantitative PCR arrays: expression profile of genes relevant to a pathway or a disease state. Methods Mol Biol 2014;1182:321-59.
34. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014;33:1590-600.
35. Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ. Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity. Transl Oncol 2013;6:355-62.
36. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005;102: 8204-9.
37. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005;37:961-76.
38. Finkel T, Serrano M, BlascoMA. The common biology of cancer and ageing. Nature 2007;448:767-74.
39. Azad A, Jackson S, Cullinane C, Natoli A, Neilsen PM, Callen DF, et al. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res 2011;9:1696-707.
40. Gorrini C, Loreni F, Gandin V, Sala LA, Sonenberg N, Marchisio PC, et al. Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proc Natl Acad Sci U S A 2005;102:9200-5.
41. Jerhammar F, Ceder R, Garvin S, Grenman R, Grafstrom RC, Roberg K. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. Cancer Biol Ther 2010;10:1244-51.
42. Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014;4:280-91.
43. Kelly CJ, Hussien K, Fokas E, Kannan P, Shipley RJ, Ashton TM, et al. Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol 2014;111:72-80.
44. Horowitz IA, Norwint H, Hall EJ. Conditioned medium from plateauphase cells. effect on growth of proliferative cells and on repair of potentially lethal radiation damage. Radiology 1975;114:723-6.
45. Phillips RM, Clayton MR. Plateau-phase cultures: An experimental model for identifying drugs which are bioactivated within themicroenvironment of solid tumours. Br J Cancer 1997;75:196-201.
46. Hahn GM, Little JB. Plateau-phase cultures of mammalian cells: An in vitro model for human cancer. Curr Top Radiat Res Q 1972;8:39-43.
47. D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br J Cancer 2014;110:2887-95.
48. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010;3:65-79.
49. Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 2000; 19:3021-31.
50. MoesDJ, Press RR, denHartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet 2012;51:467-80.